Tilray Brands (TLRY) Change in Accured Expenses (2017 - 2026)
Tilray Brands (TLRY) reported Change in Accured Expenses of -$10.6 million for Q1 2026, up 18.98% on a YoY basis from -$8.9 million in Q1 2025, and down 105.37% quarter-over-quarter from -$5.2 million in Q4 2025.
Tilray Brands (TLRY) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Tilray Brands has reported Change in Accured Expenses for 10 years, with the latest figure at -$10.6 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 18.98% year-over-year to -$10.6 million; the trailing twelve-month figure through Feb 2026 stood at -$5.9 million (up 12.42% YoY), and the FY2025 full-year result was -$22.9 million, down 10919.81% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$10.6 million, down from -$5.2 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $31.2 million in Q2 2024, with the low at -$18.0 million in Q4 2023.
- Historically, Change in Accured Expenses has averaged -$1.4 million across 5 years, with a median of -$6.3 million in 2022.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 119.73% — and 2024, when it plunged 1352.3%.
- Tilray Brands' Change in Accured Expenses stood at $4.3 million in 2022, then slumped by 515.73% to -$18.0 million in 2023, then gained by 9.01% to -$16.4 million in 2024, then surged by 68.32% to -$5.2 million in 2025, then tumbled by 105.37% to -$10.6 million in 2026.
- The last three Change in Accured Expenses figures came in at -$10.6 million (Q1 2026), -$5.2 million (Q4 2025), and -$5.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 10.02 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 23.00 Mn |
| 10 | Tilray Brands | - | - | 54.95 Mn | -10.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -10.64 Mn |
| Feb 28, 2026 | -10.64 Mn |
| Nov 30, 2025 | -5.18 Mn |
| Nov 30, 2025 | -5.18 Mn |
| Aug 31, 2025 | -5.13 Mn |
| Aug 31, 2025 | -5.13 Mn |
| May 31, 2025 | 15.02 Mn |
| May 31, 2025 | 15.02 Mn |
| Feb 28, 2025 | -13.13 Mn |
| Feb 28, 2025 | -13.13 Mn |
| Nov 30, 2024 | -16.36 Mn |
| Nov 30, 2024 | -16.36 Mn |
| Aug 31, 2024 | -8.47 Mn |
| Aug 31, 2024 | -8.47 Mn |
| May 31, 2024 | 31.19 Mn |
| May 31, 2024 | 31.19 Mn |
| Feb 29, 2024 | -6.54 Mn |
| Feb 29, 2024 | -6.54 Mn |
| Nov 30, 2023 | -17.98 Mn |
| Nov 30, 2023 | -17.98 Mn |